Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $15.33 (45.20% upside)

Current Analysts' Coverage Summary for Nektar Therapeutics (NASDAQ:NKTR)
Show:
DateFirmActionRatingPrice TargetDetailsShare
3/20/2015ZacksReiterated RatingNeutral -> Neutral$12.00ViewTweet This Rating  Share This Rating on StockTwits
3/18/2015Piper JaffraySet Price TargetBuy$15.00ViewTweet This Rating  Share This Rating on StockTwits
3/18/2015JPMorgan Chase & Co.Lower Price TargetOverweight$19.00 -> $17.00ViewTweet This Rating  Share This Rating on StockTwits
3/18/2015Jefferies GroupLower Price TargetBuy$17.00 -> $14.00ViewTweet This Rating  Share This Rating on StockTwits
3/18/2015Brean CapitalLower Price TargetBuy$20.00 -> $17.00ViewTweet This Rating  Share This Rating on StockTwits
3/18/2015Roth CapitalLower Price TargetBuy$21.00 -> $19.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2014Bank of AmericaReiterated RatingUnderperform$10.00 -> $11.00ViewTweet This Rating  Share This Rating on StockTwits
6/26/2014Ladenburg ThalmannInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
6/13/2014MKM PartnersReiterated RatingNeutral$13.00ViewTweet This Rating  Share This Rating on StockTwits
9/27/2013Cowen and CompanyReiterated RatingBuy$17.00ViewTweet This Rating  Share This Rating on StockTwits
9/27/2013William BlairReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
(Data available from 4/27/2013 forward)